US Markets

Moderna expects to start late-stage COVID-19 vaccine trial on July 27

Credit: REUTERS/Brian Snyder

Moderna Inc said on Tuesday it plans to start a late stage clinical trial for its COVID-19 vaccine candidate on or around July 27, according to its listing for the phase 3 study at clinicaltrials.gov.

Adds details of trial, background

NEW YORK, July 14 (Reuters) - Moderna Inc MRNA.O said on Tuesday it plans to start a late stage clinical trial for its COVID-19 vaccine candidate on or around July 27, according to its listing for the phase 3 study at clinicaltrials.gov.

Moderna said it will conduct the trial at 87 study locations, all in the United States.

The experimental vaccine will be tested in 30 states and Washington, D.C. Around half of the study locations are in hard-hit states like Texas, California, Florida, Georgia, Arizona and North and South Carolina.

The United States has reported record numbers of new coronavirus cases in recent days, with much of the surge coming from those states.

The federal government is supporting Moderna's vaccine project with nearly half a billion dollars and has chosen it as one of the first to enter large-scale human trials.

Tensions between the company and government scientists contributed to a delay of the trial launch, Reuters reported earlier this month.

Shares of Moderna rose about 2.5% on Nasdaq at midday.

(Reporting by Michael Erman, Editing by Franklin Paul and Richard Chang)

((michael.erman@thomsonreuters.com; +1 646-223-6021; Reuters Messaging: michael.erman.thomsonreuters.com@thomsonreuters.net))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

MRNA

Latest Markets Videos

    Reuters

    Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

    Learn More